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Abstract
Though Alzheimer's disease (AD) is a syndrome with well-defined clinical and neuropathological
manifestations, an array of molecular defects underlies its pathology. A role for the ubiquitin
proteasome system (UPS) was suspected in the pathogenesis of AD since the presence of ubiquitin
immunoreactivity in AD-related neuronal inclusions, such as neurofibrillary tangles, is seen in all AD
cases. Recent studies have indicated that components of the UPS could be linked to the early phase
of AD, which is marked by synaptic dysfunction, as well as to the late stages of the disease,
characterized by neurodegeneration. Insoluble protein aggregates in the brain of AD patients could
result from malfunction or overload of the UPS, or from structural changes in the protein
substrates, which prevent their recognition and degradation by the UPS. Defective proteolysis
could cause the synaptic dysfunction observed early in AD since the UPS is known to play a role in
the normal functioning of synapses. In this review, we discuss recent observations on possible links
between the UPS and AD, and the potential for utilizing UPS components as targets for treatment
of this disease.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb;
http://www.targetedproteinsdb.com).
Protein pathway in the disease - Introduction
The ubiquitin proteasome system (UPS) plays a role in a
variety of cellular functions. In the UPS, substrate proteins
are targeted for degradation by covalent attachment of
ubiquitin, which is mediated by an enzymatic cascade
consisting of activating (E1), conjugating (E2) and ligat-
ing (E3) enzymes. The ubiquitin-conjugated proteins are
subsequently degraded by a large multi-subunit complex,
the 26S proteasome. Substrate-specific E3s, along with
specific E2s, ensure selective protein targeting for proteol-
ysis [1,2]. In the nervous system, the UPS plays a role in
normal physiological function, while evidence gathered
in the past several years also indicates a role in neurode-
generative diseases such as Alzheimer's disease (AD) [1,2].
In this article, we discuss AD pathogenesis and how the
UPS could be linked to the early and late stages of the dis-
ease. We also suggest how further research into this area
might help to develop therapeutic strategies for AD.
Alzheimer's disease
AD is a neurodegenerative disorder of the CNS, clinically
characterized by progressive loss of memory and other
cognitive skills, resulting in severe dementia. The condi-
tion often begins with mild memory lapses and then grad-
ually advances to dementia: a progressive deterioration of
memory, language and most mental functions. During the
early stages of AD development, neurological examina-
tion is normal except for observed cognitive dysfunctions
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such as progressive worsening of memory [3-8]. The intel-
lectual decline is accompanied by the progressive extracel-
lular and intracellular accumulation of insoluble fibrous
material in the brain in the form of senile plaques and
neurofibrillary tangles (NFTs) [7].
AD is the most prevalent neurodegenerative disorder and
the most common cause of dementia [8]. Familial AD is a
rare autosomal dominant disease with early onset, caused
by mutations in the amyloid precursor protein (APP) and
presenilin (PSEN) genes, both of which are linked to amy-
loid β (Aβ) peptide metabolism [9]. Aβ is produced from
APP by sequential cleavage involving β-secretase (also
known as β-site APP cleaving enzyme 1 (BACE1)) and γ-
secretase (presenilin complex), and released into the
extracellular spaces [10]. Sporadic AD is a common heter-
ogeneous disease and is caused by a complex interaction
of genetic and environmental risk factors [9] (see figure
1).
The pathological signs of both types of AD include the
loss of medium and large pyramidal neurons, the pres-
ence of plaques and NFTs (composed of deposits of amy-
loid filaments and hyperphosphorylated tau, respectively,
surrounded by altered neurite processes and glia), a
degeneration of the neurons and the loss of synapses
[11,12]. Tau is a structural protein that is normally associ-
ated with microtubuli. In atypical conditions (such as in
AD), tau protein synthesis is upregulated and it undergoes
an abnormal post-translational modification character-
ized by hyperphosphorylation. Although multiple genetic
disturbances are believed to underlie AD, a major cause of
the disease is buildup of the toxic Aβ peptide [13].
The formation of the neurofibrillary lesions is believed to
lead to the symptoms of the disease, which result most
probably from the degeneration of nerve cells in the cere-
bral cortex and hippocampal formation, following synap-
tic loss. Defective synaptic function and memory loss is
seen in the early stages of human AD and in animal mod-
els of the disease; as such, cognitive deficits are correlated
with the loss of synapses [14]. During the early phase of
AD there is a 25–35% decrease in the density of synapses
and as the disease progresses synaptic loss is more
strongly correlated with the disease than the plaques and
tangles [15]. Animal models of AD mimic the cognitive
impairment seen in human AD [16,17].
Recent studies also suggest that AD begins with subtle
alterations in synaptic efficacy prior to neuronal degener-
ation and that diffusible oligomeric assemblies of Aβ [14]
are the cause of this neuronal dysfunction. Although there
is eventual synaptic loss in both human AD and animal
models of the disease, deficits in spatial memory and inhi-
bition of long-term potentiation (LTP; an electrophysio-
logical measure of synaptic strength) precede
morphological alterations in the animal models, suggest-
ing earlier biochemical changes in the disease [14,18,19].
Aβ treatment of cultured hippocampal neurons leads to
the inactivation of protein kinase A (PKA). Persistence of
its regulatory subunit PKAII alpha suggests that Aβ acts
directly on the signaling pathways consisting of cAMP/
PKA/cAMP-responsive element binding protein (CREB),
which are required for development of late phase LTP
[20]. Therefore, agents that enhance the PKA pathway
have potential for the treatment of AD [20]. In transgenic
mice expressing mutant APP, learning and memory is
impaired at 9–10 months of age (although no Aβ plaques
are observed in the brains of these mice) [21]. In mice car-
rying various mutations of APP, both in vitro and in vivo
LTP is impaired much before detectable Aβ deposits are
observed [22]. Also, cerebral microinjection of oligomers
of Aβ peptide inhibits in vivo LTP in rats [23].
The UPS and Alzheimer's disease
Several studies implicate neuronal UPS in the pathogene-
sis of AD (see figure 1). Abnormal deposition of highly
insoluble protein aggregates or inclusion bodies within
nerve cells is commonly observed in nervous tissue in
association with several chronic neurodegenerative dis-
eases including AD [1]. These inclusions bodies show
ubiquitin immunoreactivity in human AD brains, along
with immunoreactivity to other proteins [24-27]. The
accumulation of ubiquitin–protein conjugates in neu-
ropathological lesions was first detected in NFTs isolated
from human brain [28,29], and it is these NFTs that best
correlate with the degree of dementia [30]. It has been
shown that aggregated proteins in cell line experiments
tend to inhibit the UPS [31,32]. Alterations in the UPS
have been connected to several neurodegenerative dis-
eases [2,33]; in some instances, mutations in specific
genes have been linked to the etiology of the disease while
in other cases impairment of the UPS could be a late event
in pathogenesis [32]. Although the perturbations in UPS-
mediated proteolysis lead to pleiotropic effects on neu-
rons including cell death or degeneration, one of the early
effects is believed to be synaptic malfunction [14]. Many
recent reports from animal studies demonstrate a role for
UPS-mediated degradation of numerous substrate pro-
teins in synaptic plasticity, thus linking the UPS to normal
synaptic function [2,34]. For example, a Drosophila study
suggested that the UPS acutely regulates presynaptic pro-
tein turnover and synaptic efficacy [35]. The UPS can also
regulate long-term synaptic plasticity by degrading a cru-
cial CREB repressor in Aplysia, as shown by investigations
in our laboratory [36].BMC Biochemistry 2007, 8(Suppl 1):S12 http://www.biomedcentral.com/1471-2091/8/S1/S12
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Pathogenesis of Alzheimer's disease: potential roles of the ubiquitin proteasome system Figure 1
Pathogenesis of Alzheimer's disease: potential roles of the ubiquitin proteasome system. The figure summarizes 
the two major hypotheses (Aβ and tau) of AD pathology and the linkage of UPS to AD pathogenesis. Extracellular amyloid 
plaques consisting of insoluble Aβ peptide and intracellular neurofibrillary tangles comprising hyperphosphorylated protein tau 
are the two major features evident in the post mortem AD brain. Although the figure depicts only increased production of 
Aβ42 (a splice variant of Aβ, some familial Alzheimer's disease (FAD) mutations in APP or PSEN 1 also lead to increased Aβ42 
secretion [71]. The roles of the UPS in the steps leading to AD pathogenesis are shown in green boxes. The ubiquitin mutant 
UBB+1 is also linked to AD, though it is unclear at present how pathogenesis mediated by UBB+1 relates to the major AD 
hypotheses. Abbreviations used are: Aβ, amyloid β; AD, Alzheimer's disease; APP, amyloid precursor protein; MAP, microtu-
bule associated protein; PHFs, paired helical filaments; Ub, ubiquitin; UPS, ubiquitin proteasome system.BMC Biochemistry 2007, 8(Suppl 1):S12 http://www.biomedcentral.com/1471-2091/8/S1/S12
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Disease models, knockouts, assays
The UPS and synaptic dysfunction in early Alzheimer's 
disease
Memory impairment in AD likely results from synaptic
dysfunction, for example a defect in the ability to change
synaptic strength or synaptic plasticity. The role of the
UPS in synaptic plasticity was first observed in an inverte-
brate cellular model of long-term memory called long-
term facilitation (LTF) [37]. Specifically, the regulatory
subunits of PKA were found to be substrates for the UPS
[37]. Also, Aplysia ubiquitin C-terminal hydrolase (Ap-
uch), a homolog of vertebrate UCHL1 (ubiquitin car-
boxyl-terminal hydrolase isozyme L1), was found to
enhance the degradation of polyubiquitylated R subunit
of PKA by removing ubiquitin prior to degradation [38].
Direct electrophysiological experiments in which expres-
sion or function of Ap-Uch was perturbed demonstrated a
crucial role for the hydrolase in LTF [38]. These studies
have been corroborated by experiments on long-term
memory in mice. Furthermore, synaptic dysfunction in
hippocampal slices from APP/PSEN1 mice (an animal
model of AD), or synaptic dysfunction in hippocampal
slices from normal mice caused by treatment with oligo-
meric Aβ, was reversed by treatment with exogenous
UCHL1 [39]. The basic research on the function of
UCHL1 in synaptic plasticity [38], and the application of
this observation to treat synaptic dysfunction in AD [39],
suggests that perturbations in UPS components could be
an important causative factor in AD.
A role for UCHL1 in AD has been supported by other
observations. For example, the genetic defect in a mouse
model of gracile axonal dystrophy (gad) was shown to be
caused by an in-frame deletion that includes exons 7 and
8 of Uchl1, encoding UCHL1. The gad mice display ataxia
(lack of coordination in muscular movements), character-
ized by dragging of the hind legs. In the sensory and
motor neurons of gad mice, accumulation of Aβ and ubiq-
uitin-positive deposits occurs in a manner reminiscent of
AD pathology [40,41]. The studies by Osaka et al.[42]
demonstrated that UCHL1 ensures ubiquitin stability
within neurons. It was also shown that UCHL1 protein
level is down-regulated in idiopathic Parkinson's disease
(PD) as well as in AD brains [43]. Full-length UCHL1
appears to be a major target of oxidative damage in AD
and PD brains, and the enzyme is extensively modified by
carbonyl formation, methionine oxidation and cysteine
oxidation [44]. Also, evidence from studies on Chinese
Han population indicates a genetic association between a
serine to tyrosine mutation (S18Y polymorphism) in
UCHL1 and sporadic AD. This study concluded that the Y
allele and YY genotype of the S18Y polymorphism in
UCHL1 could confer a protective effect against sporadic
AD in female subjects [45].
The UPS and proteolytic defects in Alzheimer's disease
The ubiquitylated protein aggregates found in AD brains
are likely to result from a malfunction or overload of the
UPS or from structural changes in the protein substrates,
halting their degradation. The presence of ubiquitylated
proteins in all the AD cases [24,46,47] leads us to specu-
late that AD is associated with an inability of neurons to
degrade specific proteins or accumulated protein aggre-
gates. The following outlines how such a defect in the UPS
could occur.
A ubiquitin-conjugating enzyme, E2-25K/HIP-2, was
reported to be a mediator of Aβ-mediated toxicity and
proteasome inhibition in an animal model containing
APP mutations [48]. A ubiquitin mutant, UBB+1 (a potent
proteasome inhibitor observed in AD brains), was also
found to functionally interact with E2-25K/HIP-2-medi-
ated neurotoxicity [48]. In in vitro experiments, it was
observed that Aβ could bind and inhibit the proteasome,
thus blocking degradation of ubiquitin-conjugated pro-
teins [49,50]. Furthermore, intraneuronally accumulated
Aβ peptide in an APP/PSEN1 mutant neuronal cell culture
was also shown to inhibit both the proteasome and deu-
biquitylating enzymes (DUBs) [51]. Ubiquitin immuno-
reactivity detected in axonal spheroids and dendritic
compartments is associated with the elevated intraneuro-
nal Aβ peptide and axonopathy observed in a transgenic
mouse model of mutant APP/PSEN1 [52,53]. Results
emerging from these studies support the idea that Aβ pep-
tide's toxicity could be due to interference with ubiquitin
conjugation or direct interaction with the proteasome
itself.
It is also proposed that other causative factors in AD, such
as paired helical filaments (PHFs) of tau protein, impair
proteasome function [31]. In the brains of AD patients,
proteasome function was shown to be reduced mostly in
areas crucial for long-term memory formation such as the
hippocampus, parahippocampal gyrus superior, middle
temporal gyri and inferior parietal lobule, but not in other
areas such as the occipital lobe [54]. Another study
showed that PHFs of tau in brains of AD patients, as well
as in vitro assembly of PHFs using human recombinant tau
protein, both inhibited proteasome activity [55].
Taken together, evidence from the studies on early cogni-
tive impairment in AD patients and animal models of AD,
and the investigations on impairment of the UPS in AD,
support a role for impairment of proteolysis in early syn-
aptic dysfunction. Furthermore, there is considerable evi-
dence supporting a role for the UPS in synaptic plasticity
[2]. Although a secondary role for the UPS in AD pathol-
ogy cannot be ruled out, given the role of the UPS in syn-
aptic plasticity and in maintaining the integrity of the
synapse, perturbations in these functions could be a pri-BMC Biochemistry 2007, 8(Suppl 1):S12 http://www.biomedcentral.com/1471-2091/8/S1/S12
Page 5 of 8
(page number not for citation purposes)
mary cause of synaptic dysfunction and eventual synaptic
loss in this disease.
The presence of ubiquitin and its association with tau in
NFTs and senile plaques is a common factor in cases of AD
[1]. Accumulated ubiquitin is also present in Lewy bodies,
characteristic to some forms of the disease [26]. In all
these cases, the role of tau and other putative target pro-
teins in the pathogenesis of the disease is not understood.
Also, it is still not clear whether aberration in proteolysis
plays a causative role or only a secondary role, as
described above [56]. Conflicting reports also exist on the
E3 that ubiquitylates tau. Two reports claim that the ubiq-
uitin ligase CHIP (carboxyl terminus of Hsp 70-interact-
ing protein) targets the protein for degradation [57,58],
whereas another study argues that the ubiquitin ligase
TRAF6 is involved [59]. The discrepancy in the results
could perhaps be resolved if the phosphorylation state of
tau and the type of ubiquitin linkage that occurs with each
ligase was known. CHIP has been shown to target hyper-
phosphorylated tau and TRAF6 to polyubiquitylate tau via
Lys63 of ubiquitin (normally, polyubiquitylation occurs
through Lys48 linkage). Thus, the two ligases could act on
the same substrate under different conditions.
A more direct relationship between the ubiquitin system
and pathogenesis of AD was established with the discov-
ery of a frameshift mutation in the ubiquitin transcript,
which results in ubiquitin with 20 extra amino acid resi-
dues at its C-terminus (UBB+1). The UBB+1 protein has
been observed in the brains of AD patients [60]. UBB+1 is
an efficient substrate for polyubiquitylation; however, it
forms polyubiquitin chains that cannot be disassembled
by DUBs. Polyubiquitin chains with UBB+1 potently
inhibit the 26S proteasomal degradation of a substrate to
which they are attached [61]. This report also suggests that
the inhibitory activity of UBB+1 could be an important
determinant of neurotoxicity and that it contributes to an
environment that favors the accumulation of misfolded
proteins [62,63].
In addition, other proteins implicated in AD, such as
presenilins (PSENs) 1 and 2 (which are crucial for process-
ing APP), are linked to the UPS. Specifically, both PSEN1
and PSEN2 are targets for UPS-mediated degradation
[64]. It is not known, however, whether aberration in the
degradation of PSEN1 and PSEN2 plays any role in the
pathogenesis of AD.
Disease targets and ligands
Development of therapeutic approaches and drugs that
target components of the UPS would require a better
understanding of the role of proteolysis in AD progres-
sion. There are many potential drug targets in the UPS,
such as ubiquitin-conjugating enzymes, DUBs and the
proteasome. Among the enzymes that conjugate ubiqui-
tin to substrates, E3s are the best potential therapeutic tar-
gets because they mainly determine substrate specificity.
Since the substrate binding region imparts specificity to
E3s, allosteric modification of this region by small mole-
cules, so that specific E3s have either increased or
decreased affinity towards specific substrates, is one way
of controlling accumulation of the ubiquitylated substrate
[33]. Selective engineering of UPS components that ena-
bles modification of their delivery to a specific affected
region and subsequent degradation of specific accumu-
lated ubiquitylated proteins or protein aggregates, could
provide an alternative approach to small allosteric mole-
cules [33]. However, to date, no strong E3 candidate has
been implicated in AD.
DUBs could also be potential drug targets if a definite role
for these enzymes in AD is established. Modulation of
specific DUBs by small molecules to enhance the deubiq-
uitylation of polyubiquitin chains of mutant UBB+1 could
be another possibility as these chains inhibit proteasomes
in the AD brain [61]. A potential alternative strategy is to
exploit the role of DUBs in synaptic plasticity to counter-
act the adverse effects on this process in the AD brain. For
example, UCHL1 administration was utilized to rescue
synaptic function [39] based on previous studies on the
role of this protein in synaptic plasticity [38].
Another unexplored area for drug discovery is activation
of the proteasome. Although many inhibitors of the pro-
teasome are available, no effective drugs exist that can
enhance the function of the proteasome. Since abnormal
protein aggregation and proteasome inhibition is a com-
mon feature of AD and other neurodegenerative diseases,
enhancement of proteasome activity by small molecules
could be an efficient way to remove the aggregates that
accumulate in the brain [33]. Removal of protein aggre-
gates by the proteasome could be achieved by employing
the following strategies: (1) by increasing the activity of
the proteasome through up-regulating assembly of the
19S and 20S complexes; (2) by stimulating the recogni-
tion of ubiquitylated proteins in protein aggregates; (3) by
overexpressing or modulating the chaperone activity of
either chaperonins or ATPase subunits of 19S to unfold
the aggregated proteins and (4) by stimulating the cata-
lytic activity of the 20S core of the proteasome using small
molecules [33]. Supporting this idea, a study showed that
resveratrol, a naturally occurring polyphenol found in
grapes and red wine, lowers the levels of Aβ in cell lines by
promoting its proteasome-dependent degradation. This
suggests a possible use for this compound in therapeutic
intervention in AD [65].
With respect to ligands that modulate UPS components,
there has been little progress. Even though proteasomeBMC Biochemistry 2007, 8(Suppl 1):S12 http://www.biomedcentral.com/1471-2091/8/S1/S12
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inhibitors are being tested in clinical trial for cancer ther-
apy [66], such compounds cannot be used in the nervous
system because the role of the UPS in this system is more
complex than in cancer [2,67]. As such, non-selective pro-
teasome inhibition as a therapeutic strategy for neurode-
generative diseases could have many undesired side
effects.
New frontiers in drug discovery
Although several studies suggest a role for the UPS in AD,
systematic and thorough studies are necessary to pinpoint
how each component of the UPS could be linked to syn-
aptic dysfunction or neurodegeneration in AD. Genetic
evidence indicates that disruption of ubiquitin-mediated
processes can lead to neurodegeneration; however, the
relationship between the UPS and idiopathic neurodegen-
erative disorders is less clear. Basic research on the role of
the UPS in normal brain function is likely to guide inves-
tigations into the links between UPS components and AD,
which will allow identification of potential drug targets.
Also, studies on genetic polymorphisms within UPS com-
ponents, combined with functional validation in animal
models, are likely to aid our understanding of how
impairment of proteolysis contributes to pathogenesis of
AD. This in turn will aid the development of therapeutic
strategies. For example, even though polymorphisms in
the intron of SEL1L[68], which encodes a component of
the endoplasmic reticulum stress degradation pathway,
have been found in Italian sporadic AD patients, it is not
clear whether such polymorphisms have any effect on
proteolysis. Similarly, it remains to be determined
whether upregulation in AD brains of dactylidin, a puta-
tive RING finger ubiquitin ligase, has any functional con-
sequences [69]. Since ubiquitin-like proteins play a role in
the formation and regulation of autophagosomes [70],
modulation of this autophagic-lysosomal pathway by
UPS components could be another potential therapeutic
strategy for removal of abnormal aggregated proteins seen
in AD. A key area that requires further research is the
development of small molecules to modulate the func-
tion of UPS components.
The role of the UPS in neurodegenerative diseases, includ-
ing its connection to AD, is an intensive area of research
worldwide. Proteolysis by the UPS is essential to normal
cellular function and survival. Thus, it will be important
to distinguish the roles of UPS components in specific
neuronal functions and abnormalities such that a fuller
understanding of UPS malfunction in diseases like AD can
be obtained and therapeutic interventions be designed.
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